LIA
PVCT

LBMC Investment Advisors’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

LBMC Investment Advisors’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$1.78K – 235
2025
Q3 		$1.78K Hold
20,000
– – ﹤0.01% 234
2025
Q2 		$1.5K Hold
20,000
– – ﹤0.01% 212
2025
Q1 		$2K Hold
20,000
– – ﹤0.01% 199
2024
Q4 		$2.4K Hold
20,000
– – ﹤0.01% 196
2024
Q3 		$1.96K Sell
20,000
-2,000
-9% -$196 ﹤0.01% 193
2024
Q2 		$2.77K Hold
22,000
– – ﹤0.01% 185
2024
Q1 		$4.02K Hold
22,000
– – ﹤0.01% 184
2023
Q4 		$2.11K Hold
22,000
– – ﹤0.01% 164
2023
Q3 		$1.72K Hold
22,000
– – ﹤0.01% 160
2023
Q2 		$2.49K Hold
22,000
– – ﹤0.01% 164
2023
Q1 		$3.63K Hold
22,000
– – ﹤0.01% 162
2022
Q4 		$2.38K Hold
22,000
– – ﹤0.01% 157
2022
Q3 		$1K Buy
+22,000
New +$1K ﹤0.01% 151
2021
Q4 		– Sell
-22,000
Closed -$1 – 171
2021
Q3 		$1 Buy
+22,000
New +$1 ﹤0.01% 162
2019
Q2 		– Sell
-22,000
Closed -$1K – 102
2019
Q1 		$1K Buy
+22,000
New +$1K ﹤0.01% 99

Other funds holding PVCT

HFBOT
Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return
WPA
Wealth Preservation Advisors Chattanooga, Tennessee $120M AUM 29% 1-Year Est. Return
ACM
Academy Capital Management Waco, Texas $699M AUM 12.08% 1-Year Est. Return
FS
Financial Symmetry Raleigh, North Carolina $300M AUM 23.79% 1-Year Est. Return

LBMC Investment Advisors's PVCT Position: Q4 2025 in Review

LBMC Investment Advisors sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2025, closing a stake of 20,000 shares — an estimated $1.78K sold.

LBMC Investment Advisors first reported a position in PVCT in Q1 2019 and held it in 15 quarters. The position peaked at $4.02K in Q1 2024. 5 funds tracked by Wall St. Rank hold PVCT as of Q4 2025.

  • LBMC Investment Advisors reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2025 after selling out during the quarter.
  • LBMC Investment Advisors sold 20,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2025, an estimated $1.78K.
  • LBMC Investment Advisors first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q1 2019 and held it in 15 quarters.
  • LBMC Investment Advisors's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $4.02K in Q1 2024.
  • 5 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2025.

Based on LBMC Investment Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.